Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p): A Spanish Lung Cancer Group study

M. Taron,V. Alberola,G. Lopez Vivanco,C. Camps,R. de las Peñas,Gonzalo L. Alonso,Mariano Provencio,A Salvatierra,J. Sanchez,R. Rosell

Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p): A Spanish Lung Cancer Group study

2006

M. Taron
V. Alberola
G. Lopez Vivanco
C. Camps
R. de las Peñas
Gonzalo L. Alonso
Mariano Provencio
A Salvatierra
J. Sanchez
R. Rosell

7053 Background: SNPs are the result of historical errors in DNA replication or repair that have been inherited through generations and are now shared among individuals. ERCC1 belongs to the nucleo...

Keywords:

ERCC1
Single-nucleotide polymorphism
Cisplatin
Lung cancer
Oncology
Internal medicine
Docetaxel
Stage IV non-small cell lung cancer
Medicine
DNA replication
group study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations